We suggest that future therapeutic strategies targeting the oncogenic network of CDK4/6, MEK, PD-L1, and FOXM1 represent exciting future treatment options for MPNST patients. This evidence concerns the gene MAP2K7 and malignant peripheral nerve sheath tumor.